Efficacy and Safety of MK-1293 Insulin Glargine Compared with Originator Insulin Glargine (Lantus) in Type 2 Diabetes (T2D)

Volume 2, Issue 13, Part 3.

Nestoras Mathioudakis, MD from Johns Hopkins interviews Dr. Marc Rendell from Creighton University School of Medicine about the study: Efficacy and Safety of MK-1293 Insulin Glargine Compared Along with Originator Insulin Glargine (Lantus) in Type 2 Diabetes, presented at the June 2016 American Diabetes Association Scientific Session.

Leave a Reply

Your email address will not be published. Required fields are marked *